Mark Nicholas Namchuk, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Naltrexone | 3 | 2021 | 319 | 1.090 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2019 | 52 | 0.640 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 590 | 0.600 |
Why?
|
| Antiviral Agents | 5 | 2022 | 3053 | 0.420 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 966 | 0.390 |
Why?
|
| Morpholines | 2 | 2012 | 577 | 0.380 |
Why?
|
| Pandemics | 2 | 2022 | 8721 | 0.380 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2012 | 496 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2012 | 723 | 0.360 |
Why?
|
| Buprenorphine | 1 | 2018 | 665 | 0.350 |
Why?
|
| Antipsychotic Agents | 2 | 2021 | 3075 | 0.330 |
Why?
|
| Triazoles | 2 | 2012 | 898 | 0.320 |
Why?
|
| Weight Gain | 1 | 2019 | 2356 | 0.320 |
Why?
|
| Adipose Tissue | 1 | 2019 | 3314 | 0.280 |
Why?
|
| Drug Design | 4 | 2011 | 1039 | 0.280 |
Why?
|
| Macaca fascicularis | 2 | 2019 | 908 | 0.220 |
Why?
|
| Pharmacology, Clinical | 1 | 2003 | 23 | 0.210 |
Why?
|
| Tuberculosis | 1 | 2015 | 2009 | 0.210 |
Why?
|
| Drug Combinations | 2 | 2019 | 2075 | 0.200 |
Why?
|
| Pyrroles | 3 | 2017 | 1119 | 0.190 |
Why?
|
| Chloroquine | 1 | 2022 | 276 | 0.180 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4805 | 0.180 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 4558 | 0.170 |
Why?
|
| beta-Glucosidase | 2 | 1995 | 9 | 0.160 |
Why?
|
| Rhizobium | 2 | 1995 | 60 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2012 | 3637 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2004 | 1331 | 0.160 |
Why?
|
| Glutamate Decarboxylase | 2 | 1997 | 239 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2021 | 244 | 0.150 |
Why?
|
| Receptors, Opioid, delta | 1 | 2018 | 47 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 429 | 0.150 |
Why?
|
| Glycosides | 2 | 1995 | 99 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2019 | 8107 | 0.140 |
Why?
|
| Receptors, Opioid, mu | 1 | 2018 | 165 | 0.140 |
Why?
|
| Cricetulus | 1 | 2018 | 806 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2017 | 5691 | 0.130 |
Why?
|
| Naloxone | 1 | 2018 | 373 | 0.130 |
Why?
|
| CHO Cells | 1 | 2018 | 1372 | 0.130 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2015 | 38 | 0.120 |
Why?
|
| Janus Kinase 3 | 1 | 2015 | 75 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 1084 | 0.120 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2021 | 227 | 0.120 |
Why?
|
| Rats | 7 | 2019 | 23708 | 0.110 |
Why?
|
| GTP-Binding Proteins | 1 | 2018 | 944 | 0.110 |
Why?
|
| Valine | 1 | 2015 | 410 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2017 | 576 | 0.110 |
Why?
|
| Serine | 1 | 1997 | 825 | 0.100 |
Why?
|
| Injections | 1 | 2015 | 839 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2011 | 1376 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 13631 | 0.100 |
Why?
|
| Molecular Conformation | 2 | 2009 | 539 | 0.090 |
Why?
|
| Hydrogen Bonding | 1 | 2011 | 290 | 0.090 |
Why?
|
| Models, Molecular | 5 | 2015 | 5377 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 6209 | 0.090 |
Why?
|
| Janus Kinase 2 | 2 | 2015 | 562 | 0.090 |
Why?
|
| Structure-Activity Relationship | 3 | 2015 | 3049 | 0.090 |
Why?
|
| Aza Compounds | 1 | 2009 | 34 | 0.080 |
Why?
|
| Cell Line | 3 | 2018 | 15540 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4257 | 0.080 |
Why?
|
| HIV Infections | 1 | 2015 | 17531 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 715 | 0.080 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2009 | 174 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2011 | 4016 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 2053 | 0.070 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2007 | 28 | 0.070 |
Why?
|
| Insulin | 1 | 2021 | 6603 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 613 | 0.070 |
Why?
|
| Animals | 13 | 2019 | 168735 | 0.070 |
Why?
|
| Stereoisomerism | 3 | 2015 | 612 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 1504 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 473 | 0.060 |
Why?
|
| Sex Factors | 1 | 2019 | 10611 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 10380 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2007 | 251 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 478 | 0.060 |
Why?
|
| Dipeptides | 1 | 2007 | 386 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2206 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2009 | 1193 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 439 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2015 | 2190 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 747 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 2248 | 0.050 |
Why?
|
| Humans | 17 | 2022 | 765926 | 0.050 |
Why?
|
| Protein Binding | 2 | 2011 | 9296 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 17060 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1833 | 0.050 |
Why?
|
| Substrate Specificity | 3 | 2009 | 1750 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 1027 | 0.040 |
Why?
|
| Protein Kinases | 2 | 2004 | 1611 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5695 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 608 | 0.040 |
Why?
|
| Dogs | 2 | 2015 | 3824 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 848 | 0.040 |
Why?
|
| Mice | 7 | 2017 | 81782 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2270 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 2455 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 1672 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1997 | 283 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2007 | 2031 | 0.030 |
Why?
|
| 2,4-Dinitrophenol | 1 | 1995 | 13 | 0.030 |
Why?
|
| Dinitrophenols | 1 | 1995 | 56 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 1961 | 0.030 |
Why?
|
| Calorimetry | 1 | 1995 | 132 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 65194 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2015 | 174 | 0.030 |
Why?
|
| Sequence Analysis | 2 | 1995 | 239 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2017 | 1489 | 0.030 |
Why?
|
| COS Cells | 1 | 1997 | 1135 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2015 | 439 | 0.030 |
Why?
|
| Haplorhini | 1 | 2015 | 520 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2005 | 8279 | 0.030 |
Why?
|
| Mathematics | 1 | 1995 | 696 | 0.030 |
Why?
|
| Stiff-Person Syndrome | 1 | 1994 | 32 | 0.030 |
Why?
|
| Glucosidases | 1 | 1993 | 12 | 0.030 |
Why?
|
| Thermodynamics | 1 | 1995 | 577 | 0.030 |
Why?
|
| Deoxy Sugars | 1 | 1993 | 17 | 0.030 |
Why?
|
| Crystallography, X-Ray | 2 | 2009 | 1944 | 0.030 |
Why?
|
| Monosaccharides | 1 | 1993 | 64 | 0.030 |
Why?
|
| Cytosol | 1 | 1997 | 885 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2015 | 1167 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3716 | 0.030 |
Why?
|
| Glycoside Hydrolases | 1 | 1993 | 135 | 0.030 |
Why?
|
| Binding Sites | 2 | 2007 | 5999 | 0.030 |
Why?
|
| Cricetinae | 1 | 1997 | 2412 | 0.030 |
Why?
|
| Esters | 1 | 1993 | 213 | 0.030 |
Why?
|
| Thiocyanates | 1 | 1992 | 70 | 0.020 |
Why?
|
| Isothiocyanates | 1 | 1992 | 48 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 1993 | 406 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1992 | 204 | 0.020 |
Why?
|
| Kinetics | 2 | 1995 | 6273 | 0.020 |
Why?
|
| Serum | 1 | 2012 | 205 | 0.020 |
Why?
|
| Autoantigens | 1 | 1994 | 886 | 0.020 |
Why?
|
| Buffers | 1 | 2009 | 141 | 0.020 |
Why?
|
| Glucose | 1 | 2021 | 4335 | 0.020 |
Why?
|
| Deuterium | 1 | 2009 | 104 | 0.020 |
Why?
|
| Drug Stability | 1 | 2009 | 289 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1997 | 17596 | 0.020 |
Why?
|
| Cell Survival | 2 | 2012 | 5745 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3604 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 1995 | 3678 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2009 | 389 | 0.020 |
Why?
|
| Male | 7 | 2019 | 363815 | 0.020 |
Why?
|
| Apoptosis | 3 | 2012 | 9505 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2009 | 318 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2009 | 23597 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 2008 | 0.020 |
Why?
|
| Epitopes | 1 | 1994 | 2523 | 0.020 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1997 | 3635 | 0.020 |
Why?
|
| Oxazolone | 1 | 2007 | 59 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2007 | 624 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2007 | 490 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1994 | 2114 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2009 | 716 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 13398 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 2476 | 0.010 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 288 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2009 | 2626 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 6101 | 0.010 |
Why?
|
| Female | 3 | 2019 | 396141 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 3079 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2007 | 1880 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2009 | 1343 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 691 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5333 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2009 | 3945 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10426 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 1990 | 1919 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 3583 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1994 | 3444 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 2213 | 0.010 |
Why?
|
| Pyridines | 1 | 1990 | 2885 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 15645 | 0.010 |
Why?
|
| Rabbits | 1 | 2004 | 4729 | 0.010 |
Why?
|
| Proteins | 1 | 1992 | 5994 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1994 | 190 | 0.010 |
Why?
|
| Fluorine | 1 | 1993 | 78 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1993 | 206 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1994 | 812 | 0.010 |
Why?
|
| United States | 1 | 2021 | 72909 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 1993 | 411 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 30192 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1994 | 608 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1995 | 1677 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 1061 | 0.010 |
Why?
|
| Acetates | 1 | 1993 | 314 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1992 | 456 | 0.010 |
Why?
|
| Flunitrazepam | 1 | 1990 | 20 | 0.010 |
Why?
|
| Pentylenetetrazole | 1 | 1990 | 72 | 0.010 |
Why?
|
| Electroshock | 1 | 1990 | 120 | 0.010 |
Why?
|
| Biotransformation | 1 | 1990 | 165 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1994 | 1440 | 0.010 |
Why?
|
| Automation | 1 | 1992 | 585 | 0.010 |
Why?
|
| Amino Acids | 1 | 1995 | 1709 | 0.010 |
Why?
|
| Adult | 2 | 2021 | 223088 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 2077 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1990 | 1140 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 1527 | 0.000 |
Why?
|
| Haplotypes | 1 | 1994 | 2726 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 8037 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 4111 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 11895 | 0.000 |
Why?
|
| Receptors, GABA-A | 1 | 1990 | 623 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1992 | 2194 | 0.000 |
Why?
|
| Base Sequence | 1 | 1995 | 12405 | 0.000 |
Why?
|
| Peptides | 1 | 1992 | 4331 | 0.000 |
Why?
|
| Seizures | 1 | 1990 | 2997 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 14643 | 0.000 |
Why?
|
| Time Factors | 1 | 1992 | 40097 | 0.000 |
Why?
|
| Brain | 1 | 1990 | 27179 | 0.000 |
Why?
|
| Aged | 1 | 1994 | 171163 | 0.000 |
Why?
|
| Middle Aged | 1 | 1994 | 223016 | 0.000 |
Why?
|